Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer
A phase II trial is evaluating the efficacy of combinations of olaparib, durvalumab, cediranib, and capivasertib in recurrent or refractory endometrial cancer.
Indication
Clinical and regulatory intelligence for Endometrial Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.